Elanco Animal Health Reports Strong 2018 Fourth Quarter and Full Year Results, Confirms 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eli Lilly (LLY) PT Raised to $115 at Credit Suisse
February 7, 2019 7:59 AM ESTCredit Suisse analyst Vamil Divan raised the price target on Eli Lilly (NYSE: LLY) to $115.00 (from $112.00) while maintaining a Neutral rating following the company's 4Q earnings report. Overall, 4Q18 was mixed, as revenues beat expectations but EPS missed forecasts by a... More
Elanco Animal Health (ELAN) Tops Q4 EPS by 1c, Offers FY Guidance
February 6, 2019 6:29 AM ESTElanco Animal Health (NYSE: ELAN) reported Q4 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $799.3 million versus the consensus estimate of $805.66 million.
GUIDANCE:
Elanco Animal Health sees FY2019 EPS of $1.02-$1.12, versus the... More
